louisiana semaglutide bowel obstruction lawsuit Ozempic GLP-1 & Gastroparesis Ozempic GLP-1 Lawsuit [2026]: Gastroparesis

Ongoing research explores new formulations (oral, transdermal), longer-acting versions, combinations with other drug classes, expanded indications (heart failure, kidney disease, neurodegenerative conditions), and personalized medicine approaches identifying which patients benefit most

This ensures consistent performance and treatment safety throughout the entire procedure

Do not restart semaglutide if pancreatitis has been confirmed

If your side effects are persistent, worsening or you have any serious concerns about them, speak to your healthcare provider for advice

Same incretin pathway Little added efficacy More cost More polypharmacy Rule in practice: stop DPP-4 inhibitor before starting semaglutide unless there is a very unusual reason not to

Preclinical evidence In vivo studies utilizing the APP/PS1 mouse model of AD indicated neuroprotective properties of liraglutide